Cargando…
EVI1 as a Marker for Lymph Node Metastasis in HNSCC
Background: HNSCC is the sixth most common cancer in humans and has still a very poor prognosis. The treatment methods so far are very often associated with mutilation and impairment in the quality of life. Except for p16 expression, there are no reliable prognostic markers in HNSCC so far. Ecotropi...
Autores principales: | Idel, Christian, Ribbat-Idel, Julika, Kuppler, Patrick, Krupar, Rosemarie, Offermann, Anne, Vogel, Wenzel, Rades, Dirk, Kirfel, Jutta, Wollenberg, Barbara, Perner, Sven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038015/ https://www.ncbi.nlm.nih.gov/pubmed/32013033 http://dx.doi.org/10.3390/ijms21030854 |
Ejemplares similares
-
NR2F6 as a Prognostic Biomarker in HNSCC
por: Klapper, Luise, et al.
Publicado: (2020) -
TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
por: Klapper, Luise, et al.
Publicado: (2022) -
CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020) -
Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
por: Idel, Christian, et al.
Publicado: (2021) -
In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation
por: Krupar, Rosemarie, et al.
Publicado: (2020)